When it comes to cancer treatment, few breakthroughs have generated as much excitement over the past decade as CAR-T therapy. It’s been a genuine game-changer for people with blood cancers like leukemia and lymphoma—patients who had run out of options suddenly found themselves in remission.
But there’s a catch.
The current model of CAR-T therapy is incredibly complicated, painfully slow, and eye-wateringly expensive. We’re talking about a process that takes two to three weeks, involves collecting your own immune cells, shipping them to a centralized lab, genetically engineering them, and then infusing them back into your body. And the price tag? Hundreds of thousands of dollars for a single treatment.
That’s not a typo.
Now, a radically different approach is emerging. It’s called in vivo CAR-T, and it promises to turn your own body into the factory. Instead of removing your T cells and modifying them outside your body, in vivo therapy delivers the genetic instructions directly into your bloodstream, where your T cells get reprogrammed right then and there.
Sounds like science fiction, right? Well, it’s already happening in clinical trials across the United States, Australia, and China. And the early results are turning heads.
Let me walk you through what’s happening, because this could fundamentally change how we think about cancer immunotherapy.
The Traditional CAR-T Problem No One Likes to Talk About
First, let’s give credit where it’s due. Traditional ex vivo CAR-T therapy has saved thousands of lives. Since the FDA approved the first CAR-T product back in 2017 for acute lymphoblastic leukemia, these therapies have become a standard option for certain blood cancers.
But the manufacturing process is a nightmare.
Here’s what a patient currently goes through. First, you sit for several hours while a machine pulls your blood and separates out your T cells. That’s called leukapheresis. Those cells get frozen and shipped to a manufacturing facility somewhere across the country. At the facility, technicians use a viral vector to insert the CAR gene into your T cells. Then those engineered cells get expanded into the hundreds of millions. Finally, they’re shipped back to your hospital and infused into your veins.
Oh, and before the infusion, you also need a round of lymphodepleting chemotherapy to wipe out your existing immune cells so the new CAR-T cells have room to expand. That chemotherapy leaves you vulnerable to infections.
The entire process takes two to three weeks. For patients with rapidly progressing cancer, that waiting period can be fatal.
As one oncologist put it during a recent medical conference, the current ex vivo model is effective but limited by complexity, cost, and logistics. The in vivo approach, by contrast, is designed to function more like gene therapy. You basically write a prescription, the patient gets an infusion, and their own lymphoid organs become the bioreactor that manufactures the CAR-T cells.
That’s the dream, anyway.
What Exactly Is In Vivo CAR-T?
The concept is deceptively simple. Instead of doing all the genetic engineering in a clean room facility, you deliver the CAR gene directly into a patient’s bloodstream using some kind of delivery vehicle. That vehicle could be a lentiviral vector, an adeno-associated virus, or a lipid nanoparticle similar to what was used in the mRNA COVID vaccines.
Once inside the body, these delivery vehicles find their way to T cells and insert the CAR gene. Those T cells then start producing the chimeric antigen receptor on their surface. And just like that, you have functional CAR-T cells roaming around, hunting down cancer.
No cell collection. No weeks-long manufacturing. No lymphodepleting chemotherapy. Just a single intravenous infusion, and the patient’s body does the rest.
Researchers are exploring multiple delivery platforms for this approach. Lentiviral vectors are the most mature option, given their established safety profile and ability to achieve stable gene integration. Non-viral systems like lipid nanoparticles are also gaining traction because they offer transient CAR expression, which could provide better safety control.
Stanford researchers recently showed that they could generate CAR-T cells inside mice using the same mRNA-based lipid nanoparticle technology used in COVID vaccines. The results were impressive. About seventy-five percent of mice with B cell lymphoma saw their tumors eradicated after several doses. And crucially, the approach didn’t require any pre-treatment to deplete existing immune cells. The researchers reported seeing no toxicity even with a fairly large number of injections.
The Clinical Data That’s Got Everyone Excited
The real proof, of course, comes from human trials. And in the past year, we’ve seen some genuinely encouraging data.
Take the ESO-T01 trial conducted in China. This Phase 1 study enrolled five heavily pre-treated patients with relapsed multiple myeloma. These were patients who had already failed a median of three prior lines of therapy. They received a single infusion of an immune-shielded lentiviral vector designed to generate anti-BCMA CAR-T cells directly inside their bodies.
No leukapheresis. No ex vivo manufacturing. No lymphodepleting chemotherapy.
The results were striking. Four out of five patients achieved objective responses. Three of those four reached stringent complete remission, meaning no detectable cancer. And all four evaluable responders achieved minimal residual disease negativity by day sixty.
CAR-positive T cells were detectable in the blood as early as day seven after infusion, with peak expansion around days ten to fourteen. The responses deepened over time, with patients moving from partial response to deeper remission categories. At a median follow-up of six months, all responses were still ongoing.
One patient died before the first efficacy assessment due to spinal cord compression from progressive disease, but investigators attributed that to the underlying myeloma rather than the treatment.
Now, I should mention that this trial was stopped early in 2025, and no further enrollment was performed. Still, the data demonstrated that in vivo CAR-T generation is feasible in humans.
Then there’s KLN-1010 from Kelonia Therapeutics, which made headlines when the first US dose was administered at Winship Cancer Institute of Emory University in May 2026. This Phase 1 trial for relapsed multiple myeloma has shown promising early results, with four patients achieving MRD-negative status. The longest response lasted five months at the time of reporting.
The patients didn’t need lymphodepletion. They didn’t need to wait weeks for manufacturing. And all four saw CAR-T cell expansion around day fifteen after infusion.
The momentum has been so strong that Eli Lilly agreed to acquire Kelonia Therapeutics for up to seven billion dollars. That’s billion with a B. The deal includes a three-point-two-five-billion-dollar upfront payment, with additional milestone payouts tied to clinical and regulatory success.
If that doesn’t signal industry confidence, I don’t know what does.
But Let’s Talk About the Elephant in the Room
For all the excitement, in vivo CAR-T therapy is not without risks. And the safety data so far has been mixed.
In the ESO-T01 trial, all five patients experienced grade three or higher adverse events. Cytokine release syndrome occurred in four patients. Three patients had grade two infections. One patient developed grade one neurotoxicity. Transient cytopenias and reversible liver enzyme elevations were common.
A separate presentation at a major cancer conference highlighted these safety concerns. One patient in an early trial died, though the cause wasn’t entirely clear. The attending physician suggested the death may have been inflammatory or cardiac-related.
The early toxicity is thought to be related to an innate immune response to the viral particles themselves. But alternative mechanisms, such as T cell activation driven by the delivery vector, may also play a role.
Another open question is how well these vectors can access T cells beyond the bloodstream. Most of the T cells in your body aren’t actually circulating in your blood. They’re sitting in your lymphoid organs like the spleen and lymph nodes. In vivo delivery systems may or may not reach those cells effectively. On the flip side, being able to access that larger pool of cells could actually be an advantage if the technology works properly.
So the jury is still out.
The Industrial Scale of This Shift
One thing is clear: Big Pharma is betting heavily on in vivo CAR-T.
Beyond the Lilly-Kelonia deal, we’re seeing major investments across the board. Umoja Biopharma’s UB-VV111 became the first in vivo CAR-T therapy to receive FDA clearance for study back in 2024. The FDA has since granted fast track designation to this therapy for relapsed large B-cell lymphoma and chronic lymphocytic leukemia. AbbVie holds an exclusive option to license Umoja’s CD19-targeted candidates.
AstraZeneca acquired EsoBiotec, the Belgian company behind the ESO-T01 vector, in a deal worth up to one billion dollars.
Sana Biotechnology continues to advance its in vivo CAR-T candidate for blood cancers and B cell-mediated autoimmune disorders.
Oricell Therapeutics recently raised over one hundred ten million dollars in a pre-IPO round to advance its CAR-T platform, including in vivo technologies aimed at solid tumors.
Even smaller players like ParcelBio are entering the space with programmable mRNA platforms designed for in vivo CAR-T applications in autoimmune diseases.
The common thread? Everyone is trying to turn CAR-T from a bespoke, patient-specific manufacturing ordeal into an off-the-shelf injectable drug.
So Who Wins?
If you’re asking me whether in vivo CAR-T will completely replace traditional ex vivo CAR-T, I’d say that’s unlikely in the near term. The two approaches will probably coexist for years.
Traditional CAR-T has a proven track record, especially for hematologic malignancies. The safety profile is well understood. The long-term outcomes are documented. For patients who can tolerate the waiting period and the lymphodepleting chemotherapy, it’s a highly effective option.
But for patients with rapidly progressing disease who don’t have weeks to wait? For patients who live in regions without access to advanced cell therapy manufacturing facilities? For patients who can’t afford the astronomical costs of personalized cell therapy? In vivo CAR-T could be a genuine breakthrough.
The field is moving fast. Clinical trials are expanding. The FDA has already granted fast track status to multiple candidates. Major acquisitions are happening at valuations that would have seemed absurd five years ago.
Will there be setbacks? Almost certainly. Safety remains a significant concern. The optimal delivery vector hasn’t been settled. Dosing control is an open question. And we still don’t know how durable the responses will be compared to traditional CAR-T.
But the direction is clear. The patient’s body as the bioreactor isn’t just a catchy phrase anymore. It’s becoming a clinical reality.
And for cancer patients who are running out of options, that reality can’t come soon enough.